ReviewGene therapy2008
Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues.
Review in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Modelling in vitro gametogenesis using induced pluripotent stem cells: a review.Cell regeneration (London, England) · 2023Review
- Germ Cell Derivation from Pluripotent Stem Cells for Understanding In Vitro Gametogenesis.Cells · 2021Review
- Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Utility of Common Marmoset (Genes · 2020Review
- hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.Journal of cellular and molecular medicine · 2016Review
- Derivation of Diverse Hormone-Releasing Pituitary Cells from Human Pluripotent Stem Cells.Stem cell reports · 2016Article
- cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.Stem cell reports · 2015Article
- Concise review: making and using clinically compliant pluripotent stem cell lines.Stem cells translational medicine · 2015Review
- Article
- Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines.Differentiation; research in biological diversity · 2012Article
- Non-muscle myosin II regulates survival threshold of pluripotent stem cells.Nature communications · 2010Article
- Alternative sources of pluripotent stem cells: ethical and scientific issues revisited.Stem cells and development · 2010Review
- Regulatory issues for personalized pluripotent cells.Stem cells (Dayton, Ohio) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem cells unlike most adult stem cell populations can replicate indefinitely while preserving genetic, epigenetic, mitochondrial and functional profiles. ESCs are therefore an excellent candidate cell type for providing a bank of cells for allogenic therapy and for introducing targeted genetic modifications for therapeutic intervention. This ability of prolonged self-renewal of stem cells and the unique advantages that this offers for gene therapy, discovery efforts, cell replacement, personalized medicine and other more direct applications requires the resolution of several important manufacturing, gene targeting and regulatory issues. In this review, we assess some of the advance made in developing scalable culture systems, improvement in vector design and gene insertion technology and the changing regulatory landscape.
Indexed as
Identifiers
18004405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.